Combination therapy for type 2 diabetes maintains its position. Clinical case

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus (DM2) is a serious medical and social problem, which is associated with the epidemic growth rate of morbidity and the development of chronic complications leading to early disability, reduced quality of life and early death of patients. To date, it has been established that the optimal hypoglycemic therapy with the achievement of target metabolic parameters from the moment of diagnosis of type 2 diabetes until the end of life is the basis for the prevention of diabetic complications. Therapy with simultaneous action on various disorders is associated with great hypoglycemic potential and the ability to maintain glycemic control as the disease progresses. The article discusses the possibilities of metformin, sulfonylurea drugs, and fixed combinations. A clinical case of DM2 that developed in adulthood is presented. The patient was prescribed combination therapy with metformin and glibenclamide (Metglib Force). The possibility of this patient having MODY3 diabetes, which is characterized by good therapeutic effect of sulfonylurea drugs and specifically glibenclamide, is discussed.

Full Text

Restricted Access

About the authors

Svetlana V. Podachina

Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: spodachina@mail.ru
ORCID iD: 0000-0003-3991-1023

Associate Professor, Department of Endocrinology and Diabetology, Moscow State University of Medicine and Dentistry, Moscow, Russia

Russian Federation, Moscow

E. V. Biryukova

Moscow State University of Medicine and Dentistry

Email: spodachina@mail.ru
ORCID iD: 0000-0001-9007-4123
Russian Federation, Moscow

I. V. Solovievа

Moscow State University of Medicine and Dentistry

Email: spodachina@mail.ru
Russian Federation, Moscow

References

  1. ВОЗ. URL: http://www.emro.who.int/noncommunicable-diseases/diabetes/index.html
  2. Nickerson H.D., Dutta S. Diabetic Complications: Current Challenges and Opportunities. J Cardiovasc Transl Res. 2012;5(4):375–79. doi: 10.1007/s12265-012-9388-1.
  3. Dedov I., Shestakova M., Benedetti M.M., et al. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract. 2016;115:90–5. doi: 10.1016/j.diabres.2016.02.010.
  4. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып., М., 2019. [Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shesta- kova, A.Yu. Mayorov. 9th edition, M., 2019. (In Russ.)].
  5. Abdullah A., Peeters A., de Courten M., Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309–19. doi: 10.1016/j.diabres.2010.04.012.
  6. Verma S., Hussain M.E. Obesity and diabetes: an update. Diabetes Metab Syndr. 2017;11(1):73–9. doi: 10.1016/j.dsx.2016.06.017.
  7. Gastaldelli A., Gaggini M., DeFronzo R.A. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. Diabetes. 2017;66(4):815–22. Doi: 10.2337/ db16-1167.
  8. Ramlo-Halsted B.A., Edelman S.V. The natural history of type 2 diabetes. Primary Care: Clinics in Office Practice. 1999;26(4):771–90. doi: 10.1016/s0095-4543(05)70130-5.
  9. Ahren B., Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab. 2005;7:2–8. doi: 10.1111/j.1463-1326.2004.00361.x.
  10. Stefan N., Staiger H., Wagner R., et al. A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia. 2015;58(12):2877–84. doi: 10.1007/s00125-015-3760-z.
  11. Brunetti A. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Dabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020:(13);3611–16. doi: 10.2147/DMSO.S275898.
  12. Consentino F., Grant P., Aboyans V., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;00:1–69. doi: 10.1093/eurheartj/ehz486.
  13. Аметов А.С., Кривошеева А.А. Профилактика развития сахарного диабета типа 2. Эндокринология: новости, мнения, обучение. 2017;4:14–25. [Ametov A.S., Krivosheeva A.A. Prevention of the development of diabetes mellitus type 2. Endokrinologiya: novosti, mneniya, obuchenie. 2017;4:14–25. (In Russ.)].
  14. Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes Diabetol Metab Syndr. 2013;5(1):6. doi: 10.1186/1758-5996-5-6.
  15. Manta A. Sulfonylureas as treatment choice in Diabetes Mellitus: Where are we now? Diabetes Updates. 2019;5:1–3. doi: 10.15761/DU.10001244.
  16. Basit A., Riaz M., Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). Vasc Health Risk Manag. 2012;8:463–72. doi: 10.2147/HIV.S33194.
  17. Sola D., Rossi L., Schianca G.P. C. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–48. doi: 10.5114/aoms.2015.53304.
  18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837–53.
  19. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. М.: ГЭОТАР-Медиа, 2014. 1032 с. [Ametov A.S. Diabetes mellitus type 2. Problems and solutions. M.: GEOTAR-Media, 2014. 1032 p. (In Russ.)].
  20. Аметов А., Камынина Л., Ахмедова З. Глюкозо- и липотоксичность – взаимоотягощающие факторы при сочетании сахарного диабета тип 2 и ожирения. Врач. 2014;4:20–3. [Ametov A., Kamynina L., Akhmedova Z. Glucose- and lipotoxicity are mutually aggravating factors in the combination of type 2 diabetes mellitus and obesity. Vrach. 2014;4:20–3. (In Russ.)].
  21. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. Diabetologia, 2006;49:1711–21. doi: 10.1007/s00125-006-0316-2.
  22. Larsen P.R., Kronenberg H.M., Melmed S., Polonsky K.S. Williams textbook of Endocrinology. 10-th edition. Sauders press, 2003.
  23. Зубкова Н.А, Арбатская Н.Ю., Петряйкина Е.Е. и др. Сахарный диабет типа MODY3: клиническая и молекулярно-генетическая характеристика 9 случаев заболевания. Проблемы эндокринологии. 2014;1:51–6. [Zubkova N.A., Arbatskaya N.Yu., Petryaykina E.E. Diabetes mellitus type MODY3: clinical and molecular genetic characteristics of 9 cases. Problemy endokrinologii. 2014;1:51–6. (In Russ.)].
  24. Pearson E.R., Velho G., Clark P., et al. β-Cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations. Diabetes. 2001;50(Suppl 1):S101–7. doi: 10.2337/diabetes.50.2007.s101.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies